Charles River Laboratories International, Inc.

NYSE:CRL Stock Report

Market Cap: US$8.6b

Charles River Laboratories International Valuation

Is CRL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of CRL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: CRL ($175.55) is trading above our estimate of future cash flow value ($134.49)

Significantly Below Future Cash Flow Value: CRL is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRL?

Key metric: As CRL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CRL. This is calculated by dividing CRL's market cap by their current revenue.
What is CRL's PS Ratio?
PS Ratio2.2x
SalesUS$4.02b
Market CapUS$8.62b

Price to Sales Ratio vs Peers

How does CRL's PS Ratio compare to its peers?

The above table shows the PS ratio for CRL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.8x
QGEN Qiagen
4.1x6.43%US$8.5b
ICLR ICON
1x2.46%US$8.1b
TECH Bio-Techne
7.2x6.67%US$8.6b
BIO Bio-Rad Laboratories
2.9x2.41%US$7.6b
CRL Charles River Laboratories International
2.2x2.86%US$8.6b

Price-To-Sales vs Peers: CRL is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (3.8x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does CRL's PS Ratio compare vs other companies in the US Life Sciences Industry?

8 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.3x2.21%US$900.41m
ATLN Atlantic International
0.6x7.04%US$249.76m
SNCE Science 37 Holdings
0.6x17.47%US$34.67m
HBIO Harvard Bioscience
0.3x5.08%US$24.52m
CRL 2.2xIndustry Avg. 2.9xNo. of Companies9PS02.44.87.29.612+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CRL is good value based on its Price-To-Sales Ratio (2.2x) compared to the US Life Sciences industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is CRL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.2x
Fair PS Ratio2.9x

Price-To-Sales vs Fair Ratio: CRL is good value based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (2.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CRL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$175.55
US$197.64
+12.58%
16.19%US$265.00US$135.00n/a14
Apr ’27US$174.90
US$199.07
+13.82%
14.83%US$265.00US$155.00n/a14
Mar ’27US$178.49
US$197.20
+10.48%
14.79%US$265.00US$155.00n/a15
Feb ’27US$210.48
US$215.73
+2.50%
15.39%US$265.00US$155.00n/a15
Jan ’27US$199.48
US$197.33
-1.08%
9.73%US$230.00US$155.00n/a15
Dec ’26US$176.09
US$188.93
+7.29%
8.83%US$211.00US$155.00n/a15
Nov ’26US$180.07
US$186.87
+3.77%
9.11%US$211.00US$155.00n/a15
Oct ’26US$170.48
US$177.73
+4.25%
9.55%US$211.00US$155.00n/a15
Sep ’26US$163.31
US$172.07
+5.36%
9.81%US$200.00US$142.00n/a15
Aug ’26US$166.91
US$163.06
-2.31%
14.29%US$200.00US$108.00n/a16
Jul ’26US$154.40
US$156.14
+1.13%
17.09%US$200.00US$70.00n/a17
Jun ’26US$135.63
US$158.94
+17.19%
18.44%US$215.00US$70.00n/a18
May ’26US$116.89
US$155.28
+32.84%
25.15%US$215.00US$70.00n/a18
Apr ’26US$145.99
US$179.72
+23.11%
11.68%US$215.00US$130.00US$174.9018
Mar ’26US$165.31
US$182.69
+10.51%
14.39%US$260.12US$130.00US$178.4919
Feb ’26US$164.76
US$195.34
+18.56%
15.05%US$260.12US$152.00US$210.4818
Jan ’26US$184.60
US$215.27
+16.61%
12.74%US$260.12US$164.00US$199.4819
Dec ’25US$199.06
US$216.27
+8.65%
12.81%US$260.00US$164.00US$176.0919
Nov ’25US$180.96
US$209.80
+15.94%
13.94%US$260.00US$151.00US$180.0719
Oct ’25US$194.08
US$221.66
+14.21%
11.35%US$260.00US$175.00US$170.4817
Sep ’25US$197.75
US$224.07
+13.31%
9.96%US$260.00US$191.00US$163.3117
Aug ’25US$242.84
US$252.78
+4.09%
10.20%US$300.00US$200.00US$166.9117
Jul ’25US$203.24
US$261.05
+28.44%
9.00%US$300.00US$226.00US$154.4016
Jun ’25US$208.44
US$263.13
+26.24%
8.35%US$300.00US$226.00US$135.6313
May ’25US$232.69
US$270.67
+16.32%
7.69%US$300.00US$235.00US$116.8913
Apr ’25US$268.73
US$264.63
-1.53%
10.10%US$300.00US$200.00US$145.9914
US$197.64
Fair Value
11.2% undervalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/09 04:57
End of Day Share Price 2026/04/09 00:00
Earnings2025/12/27
Annual Earnings2025/12/27

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Charles River Laboratories International, Inc. is covered by 33 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Eric ColdwellBaird
Douglas TsaoBarclays